Genmab — November 2016
-
It´s more than ok.

-
A guidance hike was on the cards but Genmab delivered more than expected. Twenty daratumumab abstracts (six oral presentations) were accepted for ASH. We lift our 12-month target price to DKK1,470 and keep our Buy recommendation in the wake of the Q3 16 results.
-
(Y) Stærkt arbejde Helge

-
Hvad tænker du på Peter?

-
Børsen Play. Spring overskriften over. Jeg skyder bare fra hoften. https://play.borsen.dk/social/581ad7d7d99b63192e1f87f3
-
Holder foredrag i Vejle i aften omkring bla. virkningen af dara . Ville nu gerne have data med omkring solide tumorer. Det må blive en anden gang.
-
Jeg har ikke lukket Q&A chatten Solsen?
-
Dit spørgsmål er inde. Stil bare flere.
-
Jan "sætter" vel ikke kursmål?
-
Jo han gør. Han tror Genmab kommer i 2000 i 17 eller 18 :-). Jeg har aldrig set en CEO med en sådan udtalelse. Selvtilliden er i top
-
Solsen..Det er den her. Prøv at logge ind og ud.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind